Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVHIPEC-2: Primary Cytoreductive Surgery With or Without HIPEC in Stage III Ovarian Cancer
NCT03772028Phase 3Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2020
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of cisplatin in ovarian cancer, sponsored by Netherlands Cancer Institute. Started Jan 2020; status: active, not recruiting.
02
Drugs
cisplatin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03772028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03772028.